Exendin 4 polypeptide fragments and use thereof

C - Chemistry – Metallurgy – 07 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C07K 14/575 (2006.01) A61K 38/22 (2006.01) A61P 3/00 (2006.01) A61P 3/10 (2006.01)

Patent

CA 2613903

Exendin 4 polypeptide fragments having blood sugar lowering action which can be used for treating type II diabetes are provided. The polypeptide fragments have the sequence of HGEGTX1TSDLSKQX2EEEAVX3LFIEWLKNGX4PX5, wherein X1 represents Phe or Tyr, X2 represents Met, Ile or Leu, X3 represents Lys, X4 represents Gly or deletion, and X5 represents Arg or deletion. The process for preparing the Exendin 4 polypeptide fragments is also provided.

Cette invention concerne des fragments polypeptidiques d'exendine 4 ayant une action d'abaissement du taux de sucre dans le sang, qui peuvent servir à traiter le diabète non insulino-dépendant. Ces fragments polypeptidiques possèdent la séquence HGEGTX1TSDLSKQX2EEEAVX3LFIEWLKNGX4PX5, dans laquelle X1 représente Phe ou Tyr, X2 représente Met, Ile ou Leu, X3 représente Lys, X4 représente Gly ou une délétion, et X5 représente Arg ou une délétion. Cette invention concerne également le procédé permettant de préparer ces fragments polypeptidiques d'exendine 4.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Exendin 4 polypeptide fragments and use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Exendin 4 polypeptide fragments and use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Exendin 4 polypeptide fragments and use thereof will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1407480

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.